HK1090288A1 - Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity - Google Patents

Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity

Info

Publication number
HK1090288A1
HK1090288A1 HK06110903A HK06110903A HK1090288A1 HK 1090288 A1 HK1090288 A1 HK 1090288A1 HK 06110903 A HK06110903 A HK 06110903A HK 06110903 A HK06110903 A HK 06110903A HK 1090288 A1 HK1090288 A1 HK 1090288A1
Authority
HK
Hong Kong
Prior art keywords
sup
alkyl
glycogen phosphorylase
sub
inhibitory activity
Prior art date
Application number
HK06110903A
Other languages
English (en)
Inventor
Alan Martin Birch
Stuart Norman Lile Bennet
Andrew Duncan Campbell
Iain Simpson
Paul Robert Owen Whittamore
David Paul Whalley
Linda Godfrey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1090288A1 publication Critical patent/HK1090288A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK06110903A 2003-08-07 2006-09-29 Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity HK1090288A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318463.7A GB0318463D0 (en) 2003-08-07 2003-08-07 Chemical compounds
PCT/GB2004/003345 WO2005013981A1 (en) 2003-08-07 2004-08-04 Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity

Publications (1)

Publication Number Publication Date
HK1090288A1 true HK1090288A1 (en) 2006-12-22

Family

ID=27839758

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110903A HK1090288A1 (en) 2003-08-07 2006-09-29 Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity

Country Status (9)

Country Link
US (1) US20080064691A1 (xx)
EP (1) EP1658069B1 (xx)
JP (1) JP2007501779A (xx)
AT (1) ATE402696T1 (xx)
DE (1) DE602004015474D1 (xx)
ES (1) ES2309537T3 (xx)
GB (1) GB0318463D0 (xx)
HK (1) HK1090288A1 (xx)
WO (1) WO2005013981A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US20100137397A1 (en) * 2005-02-05 2010-06-03 Astrazeneca Ab Chemical Compounds
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR101381768B1 (ko) 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
ES2643602T3 (es) 2006-03-31 2017-11-23 Sunovion Pharmaceuticals Inc. Aminas y quirales
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1633709A1 (en) * 2003-04-30 2006-03-15 Pfizer Products Inc. Anti-diabetic agents

Also Published As

Publication number Publication date
ES2309537T3 (es) 2008-12-16
EP1658069A1 (en) 2006-05-24
GB0318463D0 (en) 2003-09-10
ATE402696T1 (de) 2008-08-15
WO2005013981A1 (en) 2005-02-17
EP1658069B1 (en) 2008-07-30
JP2007501779A (ja) 2007-02-01
US20080064691A1 (en) 2008-03-13
DE602004015474D1 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
HK1090288A1 (en) Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
ES2308441T3 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos.
HK1089965A1 (en) Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
PT1024138E (pt) Derivados de pirazole
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AU2015295405A1 (en) Compounds active towards bromodomains
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
WO2007142323A1 (ja) 側鎖にスピロ環構造を有する新規インダゾール誘導体
CA2526026C (en) Furazanobenzimidazoles
CN100390156C (zh) 新抗菌化合物、其制备方法和含有它们的药物组合物
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CA2577880A1 (en) Compounds useful for inhibiting chk1
PT1648880E (pt) Agentes terapêuticos úteis para o tratamento da dor
ES2308442T3 (es) Compuestos de pirazolamina para el tratamiento de trastornos neurodegenerativos.
ES2417488T3 (es) Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
BR122017023130B1 (pt) Derivado de tetrazoliloxima, métodos de produção de derivados de tetrazoliloxima
SK5782001A3 (en) Benzoylpyridazine derivative, process for the preparation thereof and pharmaceutical composition containing same
CA3211625A1 (en) 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
AU680496B2 (en) Novel bisoxadiazolidine derivative
WO2004087679A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US5760063A (en) Arylhydrazone derivatives useful as antibacterial agents
AU2009229709B2 (en) Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same
BG107908A (bg) Инхибитори на фарнезилтрансфераза
TW200510304A (en) Chemical compounds
WO2003074485A3 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120804